home / stock / azrx / azrx news

AZRX News and Press, AzurRx BioPharma Inc. From 01/28/21

Stock Information
Company Name: AzurRx BioPharma Inc.
Stock Symbol: AZRX
Market: NASDAQ
Website: azurrx.com
Menu
AZRX AZRX Quote AZRX Short AZRX News AZRX Articles AZRX Message Board
Get AZRX Alerts

News, Short Squeeze, Breakout and More Instantly...
AZRX - AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819

DELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, to...
AZRX - HTBX, TTOO among premarket losers

T2 Biosystems (TTOO) -20% despite strong Q4 & FY20 prelims.AIkido Pharma (AIKI) -18%.Seanergy Maritime Holdings (SHIP) -18%.Celsion CLSN -15%.Recon Technology (RCON) -15%.TransEnterix (TRXC) -14% after $69.25M capital raise.Ocugen (OCGN) -14%.BIOLASE (BIOL) -15%.P...

AZRX - AzurRx adds two new trial sites in Europe for phase 2b OPTION 2 extension study

AzurRx BioPharma ([[AZRX]] -7.6%) announces the activation of two additional clinical trial sites in Poland for the extension arm of the Phase 2b OPTION 2 study investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency ((EPI)) in ...

AZRX - AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients

DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Az u rRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) di...
AZRX - Top Penny Stocks To Buy Right Now? 4 To Watch Before Next Week

4 Penny Stocks to Watch on Today Despite the market starting low in the morning, by midday, many penny stocks were up on January 22nd. There are a lot of factors influencing the stock market today. With lower-priced stocks, volatility continues playing a big role. With so many diffe...

AZRX - GSAT, GME, ADMP and CLSN among midday movers

Gainers: AzurRx BioPharma (AZRX) +59%.Climate Change Crisis Real Impact I Acquisition (CLII) +59%.GameStop (GME) +55%.Adamis Pharmaceuticals (ADMP) +41%.111 (YI) +41%.Asia Pacific Wire & Cable (APWC) +37%.Polar Power (POLA) +35%.Electro-Sensors (ELSE) +31%.Mmtec (MTC) +28%.MingZ...

AZRX - Adamis Pharmaceuticals, AzurRx BioPharma leads healthcare gainers; Celsion, ViewRay among major losers

Gainers: Adamis Pharmaceuticals (ADMP) +47%, AzurRx BioPharma (AZRX) +38%, 111 (YI) +27%, Obalon Therapeutics (OBLN) +17%, iBio (IBIO) +17%.Losers: Celsion CLSN -18%, ViewRay VRAY -14%, ADiTx Therapeutics (ADTX) -14%, Passage Bio PASG ...
AZRX - AzurRx starts dosing in mid-stage cystic fibrosis study of MS1819

AzurRx BioPharma (AZRX) announces that the first two patients have been dosed in the Phase 2b OPTION 2 extension study of MS1819 using immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.The OPTION 2 extension phase design will te...

AZRX - AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients

DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today ...

AZRX - AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

Patent allowed by the USPTO that includes claims for niclosamide as a treatment for COVID-19 GI infections COVID-19 GI infections are a significant unmet clinical need; AzurRx estimates potential U.S. market size of $450-600 million or greater in first year depending on how quick...
Previous 10 Next 10